Legend:
CC = Baltimore Convention Center,
H = Hilton Baltimore
* = applied session ! = JSM meeting theme
Activity Details
124 * !
Mon, 7/31/2017,
8:30 AM -
10:20 AM
CC-319
Special Topics in Clinical Trial Design and Analysis — Contributed Papers
Biopharmaceutical Section
Chair(s): Isaac Nuamah, Janssen R & D
8:35 AM
Selection Bias in Studies with Unequal Allocation
—
Olga M Kuznetsova, Merck & Co., Inc.
8:50 AM
Phase II Trials and the Use of Registry Controls
—
Ruta Brazauskas, Institute for Health & Society-Medical College of Wisconsin ; Brent Logan, Institute for Health & Society-Medical College of Wisconsin ; Raphael Fraser, Institute for Health & Society-Medical College of Wisconsin
9:05 AM
Simulation-Based Evaluation of P-Value Quality in Phase 3 Clinical Trials
—
Jihao Zhou, Allergan, Inc. ; Ray Zhu, Allergan, Inc. ; Brandon Wales, University of California at Riverside ; Thomas Lin, University of California at Irvine
9:20 AM
Inverse Probability of Treatment Weighted Estimator for Exposure Adjusted Incidence Rate Ratio for Rare Adverse Event in Pooled Studies Controlling for Confounding by Study
—
Hui Wang, Astrazeneca ; Sudipta Bhattacharya, AstraZeneca
9:35 AM
Flexible Hypothesis Testing Method for Clinical Trials Using Composite Endpoint
—
Jin Xu, Merck ; David Li, Pfizer
9:50 AM
Optimal Design of Experiments with the Observation Censoring Driven by Random Enrollment of Subjects
—
Xiaoqiang Xue ; Valerii Fedorov, ICONplc
10:05 AM
Floor Discussion